United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Mersana Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -505.14% | - | 42.86% | 18.68% | 15.22% | 13.21% |
|---|---|---|---|---|---|---|
| ROA | -37.33% | 1.08% | 2.7% | 1.55% | 1.49% | 1.49% |
| Gross Margin | 100% | 88.5% | 88.49% | 88.37% | 88.45% | 88.18% |
| Net Margin | -170.86% | 3.34% | 7.93% | 4.78% | 4.62% | 4.66% |
| Total Assets | $144,663.00K | $147,616.04K | $150,805.32K | $152,541.68K | $152,541.68K | $152,541.68K |
| Net Income | -$69,192.00K | $1,574.80K | $4,025.72K | $2,350.94K | $2,265.98K | $2,266.96K |